It is fortunate that the three treatment modalities for cancer, surgery, radiotherapy and chemotherapy (as given by a medical oncologist), are complementary and seldom compete with one another.
KeywordsToxicity Doxorubicin Methotrexate Tamoxifen Cyclophosphamide
Unable to display preview. Download preview PDF.
- Falkson G, Klein B, Falkson H (1985) Hematological toxicity: experience with anthracyclines and anthracenes. Exp Hematol [Suppl 16] 13: 64–71Google Scholar
- Falkson G, Gelman RS, Glick JH (1987) The induction efficiency of dibromodulcitol, adriamycin, vincristine, tamoxifen and fluoxymesterone in the treatment of patients with metastatic breast cancer. Proc Am Soc Clin Oncol (abstr) 6: 49Google Scholar
- Tormey DC, Falkson G, Simon RM, Blom J, Bull JM, Lippman ME, Li S-H, Cassidy JG, Falkson HC (1979) A randomized comparison of two sequentially administered combination regimens to a single regimen in metastatic breast cancer. Cancer Clin Trials 2: 247–256Google Scholar
- Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davis TE (1982) Dibromodulcitol and adriamycin ±tamoxifen in advanced breast cancer. Am J Clin Oncol (CCT) 5: 33–39Google Scholar
- Tormey D, Gelman R, Falkson G (1983) Prospective evaluation of rotating chemotherapy in advanced breast cancer: An Eastern Cooperative Oncology Group trial. Am J Clin Oncol (CCT) 6: 1–18Google Scholar
© Springer-Verlag Berlin · Heidelberg 1989